Therapeutic effects of fludarabine-cyclophosphamide combined therapy in Iranian patients with B-cell chronic lymphocytic leukemia

authors:

avatar Kamran Moshfeghi , avatar Dr Ghasem Mosayebi ORCID , *

Koomesh: Vol.16, issue 2; 202-206
published online: September 28, 2015
article type: Research Article
received: February 01, 2014
accepted: July 09, 2014

how to cite: Moshfeghi K, Mosayebi D G. Therapeutic effects of fludarabine-cyclophosphamide combined therapy in Iranian patients with B-cell chronic lymphocytic leukemia. koomesh. 2015;16(2):e151299. 

Abstract

 Introduction: The aim of this study was to investigate the efficacy of fludarabine-cyclophosphamide combination in treatment of Iranian patients with B-cell chronic lymphocytic leukemia (B-CLL). Materials and Methods: Between April 2011 and July 2013, 20 patients with B-CLL (median age 63 years) received a regimen that consisted of fludarabine 25 mg/m2 and cyclophosphamide 250 mg/m2, days 1-3, orally, every 4 weeks, for a maximum of 6 courses. Clinical appearances and percentage of CD5+/CD19+ cells as minimal residual disease detected by flow cytometry before and 6 months after treatment. Results: The frequency of CD5+, CD5+/CD19+ and CD19+-cells were significantly high (70-90 %) in the peripheral blood of all the patients, before treatment. The percentage of CD2 and CD3+-cells were significantly increased after treatment (p